Cancer is a major public health problem, making this hard to treat disease, the second most common causes of death globally. Over the years, cancer diagnosis have risen, with about 30% of deaths attributed to cancer in Singapore. Lung cancer is by far the leading cause of cancer deaths amongst men and woman worldwide, and both the absolute and relative frequency of lung cancer has risen dramatically. Drug resistance remains to be a burden for cancer treatments, as there are still limited second-line treatment options for patients who relapse to conventional chemotherapies. Platinum-based drugs are commonly used as part of combinational therapies for lung cancer treatment; however the development of multi-drug resistance remains a challenge. Toll like receptors (TLRs) and Rig-I like receptors (RLRs), DNA and RNA sensors, are thought to be promising targets for cancer immunotherapy, signalling and alarming the immune system to recognize tumour antigens. Our preliminary data shows agonists to TLR3 (Poly(I:C)), an endosomal receptor that recognises double stranded RNA, and RIG-I (5’PPP), a cytosolic pattern recognition receptor that recognizes the tri-phosphorylated ends from double stranded viral RNA, can sensitise lung cancer cells to apoptosis, therefore suggesting a potential treatment option for this type of cancer. In addition, the absence of RIG-I results in greater sensitivity to cisplatin treatment. Whereas, the absence of Annexin A1 (ANXA1), an anti-inflammatory protein that is involved in regulation of a number of processes, including cellular proliferation, differentiation and apoptosis, results in greater resistance to cisplatin. Thus, modulation of RIG-I and ANXA1 expression in tumour cells can represent a means to predict efficacy of cisplatin treatment, which is a much needed tool in the field.